Amgen Inc. (AMGN), one of the world's largest biotechnology companies, has rallied so strongly that its stock now trades above the average analyst price target. According to S&P Global data covering roughly 34 analysts, the consensus rating is a "Hold" and the average price target is near $430 — below the roughly $460 market price in early November 2026. Because a meaningful aggregate target above the current price does not exist, the $520 level used here is a fallback objective drawn from public market commentary, not a published consensus.
For context, individual analyst targets remain wide, from about $225 on the low end to $500 at the high end (Scotiabank, September 2026). Recent post-earnings revisions include RBC Capital at $470, Oppenheimer at $480, Cantor Fitzgerald and Citigroup at $465, and Guggenheim at $435, all dated between late October and early November 2026. The $520 figure reflects the bull narrative circulating around a successful MariTide obesity readout layered on continued commercial momentum — a scenario some investors and commentators have flagged as justifying a move beyond the highest current street targets.
With shares near $460, reaching $520 implies roughly a 13% advance — a substantial but not extreme move for a large-cap biotech. Amgen's third-quarter 2026 results showed revenue of about $10.37 billion (up roughly 8.5% year over year) and adjusted EPS (earnings per share) around $7.08, prompting management to raise the midpoint of full-year guidance. Growth has been broad-based, led by Repatha, Evenity, Uplizna, Tezspire, and Imdelltra, even as legacy products such as Enbrel and Prolia face longer-term patent pressure. The path to $520 would most plausibly run through continued volume-led growth plus a positive catalyst from the pipeline, rather than further multiple expansion alone, given that the stock's trailing P/E (price-to-earnings ratio) is already in the mid-to-high 20s.
Amgen has been in a strong uptrend, with its 52-week range spanning roughly $312 to $484. The stock has recently traded near the upper end of that range, an area that can act as psychological resistance, while the prior breakout zone in the low-to-mid $400s may now function as support. A sustained close above the prior high would be needed to open a path toward the $500–$520 region, whereas a failure to hold support near $440 could signal consolidation after the extended run.
Analyst price targets typically reflect a research horizon of around 12 months, though firms do not always state a uniform timeframe. The key items to watch are the next earnings report and any updates to 2027 guidance, further analyst target revisions, and — most importantly — MariTide Phase 3 top-line data expected in the first half of 2027. Macroeconomic factors, including interest-rate decisions that influence valuations of high-P/E healthcare names, also matter for sentiment.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs (exchange-traded funds), generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. For investors tracking a fast-moving name like Amgen, such tools can offer an additional layer of signal beyond fundamental research.
The question of whether Amgen can reach $520 depends less on the current business — which is performing well — and more on whether the market is willing to assign further credit ahead of the MariTide readout. The roughly 13% move required is substantial but achievable if commercial growth persists and pipeline catalysts land. However, the fact that the average analyst target already sits below the share price is a meaningful caution: much of the optimism is priced in, and valuation offers limited cushion if data disappoints. Investors should watch earnings guidance, analyst revisions, and the MariTide top-line results as the decisive inputs.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.30% | ||
| PFE - AMGN | 51% Loosely correlated | +0.21% | ||
| GILD - AMGN | 48% Loosely correlated | +0.08% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.20% | ||
| BIIB - AMGN | 47% Loosely correlated | +1.17% | ||
| MRK - AMGN | 47% Loosely correlated | +0.55% | ||
More | ||||